SUPPLIERS QUALIFICATION
|
|
- Randell Kelley
- 6 years ago
- Views:
Transcription
1 SUPPLIERS QUALIFICATION With each passing day, new suppliers and manufacturers of packaging materials, raw materials, laboratories, etc., appear, offering products and services of different quality levels. It is, therefore, of paramount importance that the company have a robust Evaluation Program Suppliers in order to maintain then quality of products being manufactured and reduce the sanitary risk. The qualification program may include suppliers of Raw Materials, Finished Products, Packaging and Labels. The application of this Qualification Program does not ensure, by itself, the qualification of the supplier and the absence of failures. The acceptance of the results of evaluations, accreditations, selections, and possible third-party certification, are under the responsibility of the purchasing companies and contractors. In other words, they can decide negotiations regardless of the results of this process. Certification programs do not exempt companies from committing faults, errors, but show, clearly, their attitude towards their customers, to fix, in a corrective and preventive manner, all non-conformities. Tool For Management Qualification As ICH Q9 In Supplier The use of the tool " Ranking and Filtering" (RRF) in the pharmaceutical industry began in early 2002, when the FDA noted that, due to the increasing number of laboratories, it lacked the resources necessary to perform the routine inspections that were programmed. So it was essential to establish a methodology for risk analysis to prioritize inspections, i.e., define which laboratories should be audited in the first place, according to the risk of its activities involving public health. The method of " Ranking" can be defined as a risk analysis tool that enables the comparison and evaluation of the risks. If the Filtering is added to this method, a filter will be applied which will serve to define the framework of actions, about which risks should be acted upon. Objective The objective of this method is to obtain a list of the risks assessed and arranged according to their criticality. Once the list is prepared, the decision will be based on resources that are available, which indicate the risks that can be reduced. Application The application of this method is recommended when performing a risk analysis on a system with very different risks among themselves and with consequences that can be very different as well. For example, it may be helpful in Planning Audits (for manufactures for third parties, manufacturers of active ingredients, laboratories, etc.), Training Plan, Validation Master Plan, Review of Product Quality, Calibration Plan, etc. Advantages and Disadvantages Advantages: - Allows you to prioritize actions to reduce risks; - Useful when very different factors are inserted in the risk assessment; - Widely-accepted in Health Audits; Disadvantages: - There must be a good explanation for the "filtering". For example, audit the manufacturers IFA with an RV> 12; - It should be revised with an established frequency. The listing (or ranking) varies according to the actions perfomed to reduce risks;
2 Operation of an RRF The operation of an RRF can be summarized as follows: Identificarion Evaliation Ranking & Filtering Ranking Matrix Filtering Matrix FILTER RANKED LIST 1. Identification Similarly to other methods of analysis, it is first necessary to identify the risks. In order to perform this stage of RRF, a brainstorming session is desirable,, where different people from the company can show the related risks. A good way to start a brainstorming session can be a set of several questions to the people who are supposed to identify the risks. Once the risks are identified it is convenient to group them by categories, for example: - Quality System; - Analytical Results, - Manufacturing plant single-purpose or multi-purpose. - etc. These groupings are called risk factors. It is recommended that the risk factors meet a number of requirements for the model of RRF to be consistent:
3 Logical Consistency Compatible with the organization and legislation Equality Exhaustive list, not to leave out any relevant risk; The resulting priorities should be easily interpreted by the management; The number of factors considered must be enough to meet the GMP rules in detail and not to create questions during the inspection; Compatible with the existing database in the organization to facilitate the information search; The factors considered should well represent the interests of the various parts affected. This is reflected especially in the selection of the "weights"; Compatible with the "company culture". The factors chosen should be easily assimilated and familiar; Factor Factor 1 (WT) Level of Score Description Factor 2 (WT) Example of allocation table values Each risk factor (or risk value) for each item corresponds to each element analyzed or risk factor by level of risk associated with one of the parameters. The risk associated with a part of the system will be the sum of those products, as represented in the following formula: Logical Structure Should not be too many analysis is not very complex; so the Avoid categorizing better (many sub-factors) the best known and worse the more unknown; it must be homogeneous. 2. Evaluation To conduct the risk assessment system, you must first assign the values of each risk factor. Once analysed all risk factors, each score is multiplied by the weight factor associated with the relative Effective Score. The final score ( Level) is obtained by summing the actual points of each risk factor. It is recommended that the weights add up to a 10 or 100 etc. in order to easily justify the % assigned to each one. Each risk factor is assigned to a numerical value called weight. Since all risk factors do not have the same importance, this value can be used. For example, in an evaluation of suppliers of packaging material, the risk factor "Quality System ISO" should have a higher weight than the risk factor "Geographical location of the supplier", because the former represents a greater risk of receiving or not the packaging material in conformity. Each risk factor may be subdivided into different levels of risk. In the previous examples, you can assign a score 1 ISO 9001/14001 is presented, a score 2 if only an ISO certification is presented and 3 there is not any ISO 9001 certification. A table can be created (or risk matrix) which will serve to list each item or part of the system with the assigned values: Item Item 1 Item 2 Item 3 Factor 1 Factor 2 3. Ranking & Filtering Factor 3 Value (RV) Comments The last step of this analysis method is to list the items according to the risk value obtained from the highest to the lowest value (ranking), so it is possible to prioritize the risks
4 of higher value and make sure that the items with higher value are treated first. If there are no resources to act on all items, it must be decided which risk will be the first to receive an action. They will probably be those on the top of the list by applying the "filtering". Below is an example of a table containing the end result of a " Ranking": Kind of material (IFA, packaging.) Manufacturer Value IFA X 25 IFA Y 28 IFA Z 32 Because companies do not have a sufficient number of professionals to perform all audits, audits with less " Value" are postponed to the following year Acquisition of relevant information about the supply chain for the Packaging and Raw Materials Approval of suppliers of packaging materials or raw materials Permit for the specification of packaging material or raw material Packing material or starting bought and used in the manufacture of finished products Analysis and trends of results Qualification of the supplier of packaging materials and raw materials Product Periodic Review The audit plan for the next year should take into account the suppliers / manufacturers who were previously excluded from the audit plan. A risk factor that represents the time elapsed since the last audit or if the audit could not be performed according to a previous audit plan c can be inserted into a table by assigning values. Supplier Qualification Process The qualification process for suppliers of packaging materials and raw materials can be designed in a sequential flow of activities as follows: Understanding the nature of the packaging material or raw material Understanding the nature of the finished products Acquisition of relevant information on the packaging or manufacturer of raw materials 1. Understanding the nature of the packaging material or raw material The nature of the packaging material or raw material may have impact on the type and quantity of information being requested from a supplier at the time of qualification. If the packaging material is a pre-printed material, primary or secondary component. If the raw material is a pharmaceutical excipient active ingredient or bulk. In compliance with any international standard ( e.g., BP, USP). Specif grade of the material to be used and its physical critical properties If the material is of human, animal or biological origin. 2. Understanding the nature of the finished products The nature of Finished Goods that are used in packaging materials and raw materials may
5 present an impact on the type and quantity of information that will be requested to a supplier at the time of qualification. The type of medication (e.g., non-sterile, herbal medicine). Identification of potential consumers of the finished product. Other ingredients that can be used in formulations of finished products. Any potential stability issue regarding the finished product. Any potential manufacturing issue regarding the finished product. Considerations of the nominations of the finished product and label. Identification of the dosage instructions of the finished product. 3. Acquisition of relevant information about the manufacturer of the packaging material or raw material The acquisition of relevant information, including the identification of the manufacturer of the packaging material or the raw material, is necessary to achieve the qualification of the supplier. It may not be possible to deal directly with the manufacturer of the packaging material or raw material. If this occurs, it may be possible to obtain information about the manufacturer through their supplier. A questionnaire or a standard form to collect this information may be used. A copy of the Site Master File from the manufacturer can be helpful. This information can also help the risk assessment which should be conducted before adopting the reduction test / analysis. The place of manufacture of the material and alternative sites used. The condition of GMP of all manufacturing sites. The quality system in which the manufacturer is inserted. Evaluation of the packing material or the raw material against the manufacturer requirements, textbooks or other requirements. Who provides the Certificate of Analysis (C of A) for the raw material. Note that it is unacceptable that the results of manufacturer C of A are transcribed from the original C of A to the letter from the supplier. Acceptability of the samples provided with reference to the chemical, microbiological and physical attributes. If the manufacturing site has been audited and by whom. If the manufacturer has been contacted in previous occasions or other materials are supplied by this manufacturer. Any other material is being produced at the manufacturing site. Information about how the material is produced and what impurities may be present as a result of the production process. Relevant information about the testing methods used by the manufacturer. The real supplier of the tests that are documented in the Certificate of Analysis. Information about pesticides, process validation, and validation information of the analytical method. Confirmation that the manufacturer represents a single and specific source of the material. The manufacturer must collect and mix materials from various sources, which makes difficult the reduction of tests in this supplier qualification. Attributes of stability of raw materials and requirements for transportation of the material.
6 4. Acquisition of relevant information about the supply chain of packaging material and raw materials Each step in the supply chain may have potential impact on the quality of the packaging material or raw material. The identification of all interactions with the material between the output of the manufacturer and the final delivery of the finished product may be useful. Location of Manufacturer. Location of Supplier For herbal materials, location of harvest, harvest time, herbs identification and methods of preparation (extraction, for example). If the provider stores the material and the location and types of other materials are stored next to the material of interest. If the supplier fragments the material and the environment and the manner in which this activity is conducted. If the supplier has a technical agreement with the manufacturer and the contents of this agreement (for example, changes of material, such as method of manufacturing or supplying of material). The number of middlemen and the control of the transport chain from the manufacturer to the manufacturer of the finished product. Any material with requirements for specific storage such as refrigeration or humidity control. The time required for raw materials usually is received at the site. 5. Supplier approval of packaging material or raw material Information obtained in previous steps are evaluated by the Quality Unit and, if acceptable, the supplier may be approved When the raw material is supplied by a manufacturer that has a license and GMP certification issued by a health authority, then no other qualification is required from the manufacturer. The license or certification must cover the manufacturing of the specific material or the bulk and a GMP agreement must be established. To other suppliers a formal agreement that covers all relevant issues is recommended. how the supplier's approval system will rank the various levels or status of its approved suppliers and qualified. 6. Authorization of the specification of packaging material or raw material. The specification must be based on a paper when available and any relevant information provided by the manufacturer. If the material is supplied by a distributor / supplier, and if this is the case, the manufacturer has identified and documented the material specification. If C of A clearly provides documents of the test methods used, the acceptable specification limits and the results obtained by the manufacturer. If all tests performed by the manufacturer are compendial tests. If any non-compendial tests are properly validated. 7. Packing material or raw material purchased and used to manufacture the finished product In this phase, each delivery of a specific number of batches of raw materials would be approved by the Quality Unit after the total sample and all tests with satisfactory results.
7 Typically, three batches of raw material would be subjected to a complete sampling and testing, however, specific requirements of raw material may change this number. The standards that exist for the raw material. Number of deliveries received per year. Number of different batches received per year. The history of the Supplier. History of the raw material manufacturer. 8. Analysis and Data Trends All relevant data can be revised in accordance with the acceptance criteria defined. The information can be used to support a justification for a reduced sampling. The review of the physical condition of each lot of raw material. Review of the documentation that accompanied each batch of raw material. If all the results meet the specification of requirements. Review of any results out of specification or out of trend and any investigation followed by the conclusions. A statistical comparison of the results of tests performed in their own laboratory against the results issued by the manufacturer of the raw material when appropriate. 9. Qualification of the supplier of packaging material or raw material Assessment of all information collected from the supplier of packaging material or raw material. and it can be achieved through documentation review, questionnaires and audits. The minimum information to be evaluated by the Quality Unit must include a supplier qualification questionnaire completed and, if possible, an on-site audit of the manufacturing of raw materials. The information can be used to support the qualification of the supplier. Assessment of the supplier qualification questionnaire. The assessment of any other relevant information. Evaluation by an on-site audit of manufacturing and supplier, as required. If appropriate measures are in place to ensure the origin of the raw material in order to protect it against counterfeit materials. 10. Periodic Review As part of the qualification process, a program of periodic review must be established. This program should include a mechanism to remove the qualification status of a supplier of packaging material or raw material and should prevent the use of limited sampling and reduced tests until the critical issues identified are satisfactorily resolved. The Quality System of the manufacturer of raw material. The Quality System of the supplier.. The quality of batches of raw material received. Documentation reviews. Analysis of trends. Information obtained through questionnaires and audits of suppliers. This evaluation must be conducted by authorized personnel from the Quality Unit
8 Considerations About The Criticality Of Suppliers The buyer or contractor must target their suppliers as critical and noncritical" taking actions of qualification or disqualification, depending on the scores achieved. Depending on the results of evaluations of the supplier, they can still be considered "qualified", or negotiate a period to qualify or even, depending on the number of nonconformities and the possible impacts that these are causing or may cause in the buyer's processes, in the raw materials, finished products and even in the final customers (brokers, traders, users, consumers) they can be "Disqualified". In spite of the criteria established in this program, each company has their independence to set their own criteria for accreditation, to select and evaluate suppliers. It can set their criteria for criticality, taking into account, among others, aspects of health and safety, logistics, fulfilment of agreed schedules, productivity, financial aspects, if it is the exclusive supplier, existing certificates, index of the nonconformities in the receiving and process, prices, types of freight, warranties, location, among other factors. Bibliography - ANVISA Resolução da Diretoria Colegiada RDC 17 Regulamento Técnico de Boas Práticas de Fabricação de Medicamentos 16 de abril de ICH Harmonized Tripartite Guideline Q9 Quality Management. - ICH Harmonized Tripartite Guideline Q10 Pharmaceutical Quality System. - PIC/S Guide to Good Manufacturing Practice for Medicinal Products, January 2009 including Annexes. - Sampling and Testing of Complementary Medicines. May Technical Working Group on Complementary Medicines. - Technical Guidance on the interpretation of Manufacturing Standards. Supplier Qualification: Technical Working Groups (TWG) on Non-Sterile Medicines & Complementary Medicines. V1.0 September Kesia Pires Project Manager of Telstar Life Science value service - Brasil Conclusion The process of qualifying suppliers can be developed in different ways, being the example above only one of them. In this article, it was also demonstrated the possibility to use tools for prioritization of audits of suppliers in order to establish a "Supplier Qualification Program" that can be coherent and attainable.
Subpart B Organization and Personnel, 21 CFR Responsibilities of the quality control unit.
FDA inspections continue to focus on CGMP violations related to basic GMP controls. A survey of Warning Letters issued in 2013 on CMC (Chemistry / Manufacturing / Controls) violations reveals an emphasis
More informationGood Manufacturing Practices Purpose and Principles of GMP. Tony Gould
Good Manufacturing Practices Purpose and Principles of GMP Tony Gould Why GMP? Provides a high level assurance that medicines are manufactured in a way that ensures their safety, efficacy and quality Medicines
More informationUNICEF s Quality Assurance System for Procurement of Finished Pharmaceutical Products
UNICEF s Quality Assurance System for Procurement of Finished Pharmaceutical Products UNICEF Industry Consultation with Manufacturers and Suppliers of Finished Pharmaceutical Products 29 th 30 th September
More informationEUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL. EudraLex The Rules Governing Medicinal Products in the European Union
EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Brussels, 25 October 2005 EudraLex The Rules Governing Medicinal Products in the European Union Volume 4 EU
More informationAuthorization and GMP Regulation
Superintendência de Inspeção Sanitária SUINP Authorization and GMP Regulation São Paulo, August 2 nd 2014. Authorization Companies need Anvisa authorization (AFE) to begin comercial activities in Brazil
More informationProduct quality review for listed Complementary Medicines
Technical Guidance on the Interpretation of Manufacturing Standards Product quality review for listed Complementary Medicines Technical Working Group (TWG) on Complementary Medicines Issue 9-4/3/2010 About
More informationCALIBRATION AND QUALIFICATION OF EQUIPMENTS IN THE PHARMACEUTICAL INDUSTRY: EMPHASIS ON RADIOPHARMACEUTICALS PRODUCTION
2011 International Nuclear Atlantic Conference - INAC 2011 Belo Horizonte, MG, Brazil, October 24-28, 2011 ASSOCIAÇÃO BRASILEIRA DE ENERGIA NUCLEAR - ABEN ISBN: 978-85-99141-04-5 CALIBRATION AND QUALIFICATION
More informationRegulatory. Supplier Qualification A Review
Supplier Qualification A Review Abstract: It is a GMP requirement to certify the vendor to deliver high quality and safe medicines, and to prevent recalls, deaths, adverse events, and serious illness due
More informationPhase Appropriate GMPs for IMPs. Presented by: Karen S. Ginsbury For: IFF, October 31, Nov 02, 2017
Phase Appropriate GMPs for IMPs Presented by: Karen S. Ginsbury For: IFF, October 31, Nov 02, 2017 1 Lets start with References https://mhrainspectorate.blog.gov.uk/2016/0 5/20/manufacture-of-investigationalmedicinal-products-frequently-askedquestions/
More informationContents. Contents (13) 1 Production (23)
1 Production (23) 1.A Sanitation (27) 1.A.1 Organisational prerequisites (27) 1.A.2 Sources of contamination (28) 1.A.3 Responsibilities and implementation (29) 1.B Personnel hygiene (31) 1.B.1 Clothing
More informationEMPROVE For Raw and Starting Materials & For Filtration Devices and Single Use Systems. Jan Thomsen Warsaw, November 15 th, 2016
EMPROVE For Raw and Starting Materials & For Filtration Devices and Single Use Systems Jan Thomsen Warsaw, November 15 th, 2016 2 Content Emprove - An Introduction Emprove for Raw and Starting Materials
More informationGuidelines for Process Validation of Pharmaceutical Dosage Forms
Guidelines for Process Validation of Pharmaceutical Dosage Forms Version 2.1 Date issued 21/02/2010 Date of implementation 21/05/2010 31 August 2010 Page 1 of 20 Guidelines for Process Validation of Pharmaceutical
More informationPHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME. PI July 2018
PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME PI 045-1 1 July 2018 GUIDELINES ON THE FORMALISED RISK ASSESSMENT FOR ASCERTAINING THE APPROPRIATE GOOD MANUFACTURING
More informationEuropean Medicines Agency Inspections
European Medicines Agency Inspections London, 14 July 2008 Doc. Ref. EMEA/INS/GMP/361819/2008 COMMUNITY PROJECT ON THE PRACTICAL IMPLEMENTATION OF THE NEW OBLIGATIONS FOR MANUFACTURING AUTHORISATION HOLDERS
More informationDocumenta tion and Records
Documenta tion and Records Page 1 of 30 Training Outcome of the Module: After completing this module, you will be able to: Recognize the importance of procedures Recognize the importance of record keeping
More informationAAMI Quality Systems White Paper: Comparison of 21 CFR Part 820 to ISO 13485:2016 1
AAMI s White Paper Comparison of 21 CFR Part 820 to ISO 13485:2016 February 2017 AUTHORS Seb Clerkin, GMP Advisory Services Nicola Martin, Owner, Nicola Martin Consulting Jack Ward, Owner, Ward Sciences
More informationConducting Supplier Audits: Ensure Validation Compliance
Conducting Supplier Audits: Ensure Validation Compliance Presented by: Gamal Amer, Ph. D. Principal Premier Compliance Services, Inc. All rights reserved. Do not copy without permission. 1 Outline Why
More information18.H Questionnaire for preparing GMP-inspections
Questionnaire for preparing -inspections Questionnaire for preparing -inspections Here you will find answers to the following questions: What questions are typically asked during inspections based on current
More informationPROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES: VALIDATION, APPENDIX 7:NON-STERILE PROCESS VALIDATION
1 Working document QAS/13.527/Rev.2 August 2014 RESTRICTED 2 3 4 5 6 7 8 9 10 PROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES: VALIDATION, APPENDIX 7:NON-STERILE PROCESS
More informationGMP Inspection Deficiencies Review of Deficiencies Observed in 2013.
GMP Inspection Deficiencies 2013 Review of Deficiencies Observed in 2013. Executive Summary The most frequently encountered defect categories raised over the previous five years have remained relatively
More informationá1225ñ VALIDATION OF COMPENDIAL PROCEDURES
1640 á1224ñ Transfer of Analytical Procedures / General Information USP 39 THE ANALYTICAL PROCEDURE The procedure should be written with sufficient detail and explicit instructions, so that a trained analyst
More informationEUROPEAN INDUSTRIAL PHARMACISTS GROUP. Guidance on CPD for QUALIFIED PERSONS
EUROPEAN INDUSTRIAL PHARMACISTS GROUP Guidance on CPD for QUALIFIED PERSONS EIPG Guidance on CPD for QP Continuing Professional Development for Qualified Persons, Technical Directors and other Responsible
More informationAnnex 4. Guidance on good manufacturing practices: inspection report. Background
Annex 4 Guidance on good manufacturing practices: inspection report Background The need for revision of the Guidance on good manufacturing practices: inspection report (World Health Organization (WHO)
More informationINTERNATIONAL RESEARCH JOURNAL OF PHARMACY ISSN Review Article
INTERNATIONAL RESEARCH JOURNAL OF PHARMACY www.irjponline.com ISSN 2230 8407 Review Article INTRODUCTION AND GENERAL OVERVIEW OF PHARMACEUTICAL PROCESS VALIDATION: A REVIEW Pandita Rachna* 1, Rana A C
More informationEU and FDA GMP Regulations: Overview and Comparison
THE QUALITY ASSURANCE JOURNAL, VOL. 2, 55 60 (1997) EU and FDA GMP Regulations: Overview and Comparison The increasing emphasis on global supply of drug products, as well as starting materials and investigational
More informationUNICEF Quality Assurance in the procurement of medicines
UNICEF Quality Assurance in the procurement of medicines Peter S. Jakobsen 30 October 2006 Quality Assurance Centre SUPPLY DIVISION Today s presentation addresses 3 questions: How is UNICEF involved in
More informationSITE MASTER FILE For MHRA
ABC CO., LTD. For MHRA Prepared by Date Approved by Date Verified by Date Document No.: SMF, Version No: 01, Effective Date: 09/05/06 Document No.: SMF Version No.: 01 Effective Date: 09/05/06 Page 2 of
More informationExcipients Facing Increased Scrutiny How to Use Secondary Reference Standards to Help Maintain Regulatory Compliance
Excipients Facing Increased Scrutiny How to Use Secondary Reference Standards to Help Maintain Regulatory Compliance by Tom Savage, NSF International Since 2008, when patient deaths were first linked to
More informationPROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES: VALIDATION, APPENDIX 7:NON-STERILE PROCESS VALIDATION
1 Working document QAS/13.527/Rev.1 April 2014 RESTRICTED 2 3 4 5 6 7 8 9 10 PROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES: VALIDATION, APPENDIX 7:NON-STERILE PROCESS
More informationGUIDELINES FOR INTRODUCING A LOCALLY MANUFACTURED NEW PHARMACEUTICAL PRODUCT ON THE UGANDA MARKET
GUIDELINES FOR INTRODUCING A LOCALLY MANUFACTURED NEW PHARMACEUTICAL PRODUCT ON THE UGANDA MARKET National Drug Authority Head Office Rumee Towers Plot 19, Lumumba Avenue P. O. Box 23096 Kampala, Uganda
More informationRECOMMENDATIONS FOR DIETARY INGREDIENT PROCESSORS
RECOMMENDATIONS FOR DIETARY INGREDIENT PROCESSORS Facilities that manufacture 117, pack, or hold dietary supplements are subject to the regulations in 21 CFR Part 111, while those that manufacture, pack,
More informationDrug Quality Assurance: Systems at ChemCon Author: Dr. Peter Gockel
Drug Quality Assurance: Systems at ChemCon Author: Dr. Peter Gockel On February 13th, 2006, the FOOD AND DRUG ADMINISTRATION (FDA) implemented a revision to the Compliance Program Guidance Manual for active
More informationEudraLex. Part I1 Chapter 6: Quality Control
EudraLex The Rules Governing Medicinal Products in the European Union Volume 4 EU Guidelines tofor Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use Part I1 Chapter 6: Quality
More informationInternational Pharmaceutical Excipients Council Of The Americas
October 6, 2008 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Subject: FDA Draft Guidance for Industry, Residual Solvents in Drug
More informationOn the Q&A to the Guideline for Common Technical Documents
To: Public Health Bureau Prefectural Government Letter from PFSB/ELD 22 nd October 2001 From: Evaluation & Licensing Division, Pharmaceutical & Food Safety Bureau, The Ministry of Health, Labour and Welfare
More informationUNICEF Quality Assurance in the procurement of medicines
UNICEF Quality Assurance in the procurement of medicines Peter S. Jakobsen October 2008 Quality Assurance Centre SUPPLY DIVISION 2 Today s presentation addresses 3 questions: How do UNICEF manage quality
More informationGMP GUIDELINES. GMP Guides from Industry Organisations. FDA cgmp WHO GMP. cgmp Guide Drugs 21 CFR 210 GAMP. ISPE Technical Guides
FDA cgmp cgmp Guide Drugs 21 CFR 210 cgmp Guide Drugs 21 CFR 211 cgmp Guide Medical Device 21 CFR 808, 812, 820 cgmp Guide Biologics 21 CFR 600, 606, 610 Guideline List Human Drugs Guideline List Biologics
More informationGMP Manual. Contents. Contents (1) 1 Pharmaceutical Quality System (PQS) 2 Personnel
GMP Manual GMP Manual 1 Pharmaceutical Quality System (PQS) 1.A Preface 1.B The road to a Pharmaceutical Quality System 1.C Introduction to the PQS 1.C.1 General requirements 1.C (1) 1.C.2 Documentation
More informationPharmaceutical Reference Standards: Overview and Role in Global Harmonization
Matthew Borer, Ph.D., Advisor Pharmaceutical Reference Standards: Overview and Role in Global Harmonization 3rd DIA China Annual Meeting Beijing, China, 16-18 May, 2011 What is a Pharmaceutical Reference
More informationChristine Oechslein. GMP Focus. Managing Process Validation. A Drugmaker s Guide. PDF Download. Excerpt from the GMP MANUAL
Christine Oechslein GMP Focus Managing Process Validation A Drugmaker s Guide PDF Download Excerpt from the GMP MANUAL Bibliographic Data of the Deutsche Nationalbibliothek: http://dnb.ddb.de ISBN: 978-3-95807-056-1
More informationCUSTOMER AND SUPPLIER ROLES AND RESPONSIBILITIES FOR 21 CFR 11 COMPLIANCE ASSESSMENT. 21 CFR Part 11 FAQ. (Frequently Asked Questions)
21 CFR Part 11 FAQ (Frequently Asked Questions) Customer and Supplier Roles and Responsibilities for Assessment of METTLER TOLEDO STARe Software Version 16.00, including: - 21 CFR 11 Compliance software
More informationJournal of Chemical and Pharmaceutical Research
Available online www.jocpr.com Journal of Chemical and Pharmaceutical Research ISSN No: 0975-7384 CODEN(USA): JCPRC5 J. Chem. Pharm. Res., 2011, 3(6):88-98 Conduct of Inspections for Pharmaceutical Manufactures
More informationISO 22000:2005 SYSTEMKARAN ADVISER & INFORMATION CENTER SYSTEM KARAN ADVISER & INFORMATION CENTER FOOD SAFETY MANAGEMENT SYSTEM ISO 22000:2005
SYSTEM KARAN ADVISER & INFORMATION CENTER FOOD SAFETY MANAGEMENT SYSTEM ISO 22000:2005 WWW.SYSTEMKARAN.ORG 1 www.systemkaran.org Foreword... 6 Introduction... 7 Food safety management systems Requirements
More informationExcipient Certification: Schemes and Auditable Standards - the role in Supplier Qualification
Excipient Certification: Schemes and Auditable Standards - the role in Supplier Qualification European Compliance Academy Vienna, 20 th & 21 st October 2009 Dr Iain Moore Chair Certification Committee
More informationGood practices in quality control in pharmaceutical industry - Overview of regulatory guidelines
Review Article Good practices in quality control in pharmaceutical industry - Overview of regulatory guidelines Chagi Venkatesh*, S. B. Puranik ABSTRACT Good practices in quality control (QC) department
More informationHosting Inspections from foreign countries: PMDA (Japan) ANVISA (Brazil)
Hosting Inspections from foreign countries: PMDA (Japan) ANVISA (Brazil) Kathrin Abelein Vice President Quality, R-Pharm, JSC First Russian GMP Conference 20. 22. September 2016 Agenda General information
More informationEUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. EudraLex. The Rules Governing Medicinal Products in the European Union
Ref. Ares(2014)968036-28/03/2014 EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Health systems and products Medicinal products quality, safety and efficacy Brussels, 28 March 2014 EudraLex
More informationWHO guidelines on quality risk management
Annex 2 WHO guidelines on quality risk management 1. Introduction 62 1.1 Background and scope 62 1.2 Principles of quality risk management 64 2. Glossary 67 3. Quality risk management process 70 3.1 Initiating
More informationRegistration and renewal of the credential certificate for registration
Registration and renewal of the credential certificate for registration 1. Qualification of the applicant: 1.1 Must be a holder of the license to manufacture or import the psychotropic substances of category
More informationMaterion AMTS Supplier Quality Manual
Advanced Materials Technologies and Services Inc. Materion AMTS Supplier Quality Manual Supplier Name: Supplier Address: Suppliers shall review the attached Supplier Quality Manual and acknowledge receipt
More informationGUIDE TO GOOD MANUFACTURING PRACTICE FOR MEDICINAL PRODUCTS
PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME GUIDE TO GOOD MANUFACTURING PRACTICE FOR MEDICINAL PRODUCTS PH 1/97 (Rev. 3), 15 January 2002 ANNEX 15 QUALIFICATION AND
More informationAnnex 14 WHO guidelines for drafting a site master file 136
World Health Organization WHO Technical Report Series, No.961, 2011 Annex 14 WHO guidelines for drafting a site master file 136 1. Introduction 2. Purpose 3. Scope 4. Content of site master fi le Appendix
More informationEuropean Medicines Agency Evaluation of Medicines for Human Use
European Medicines Agency Evaluation of Medicines for Human Use London, 22 February 2006 EMEA/CHMP/BWP/49348/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON SIMILAR BIOLOGICAL MEDICINAL
More informationQuality Assessment & GMP Similarities & Differences
Quality Assessment & GMP Similarities & Differences EMEA, Monday 26 th October 2009 Cormac Dalton Inspector Irish Medicines Board Date 12-Oct-09 Slide 1 Content Overview of commonalities & differences
More informationWARNING LETTER AUG 3, 2016
Ropack, Inc. 8/3/16 Department of Health and Human Services Public Health Service Food and Drug Administration 10903 New Hampshire Avenue White Oak Building 66 Silver Spring, MD 20993 WARNING LETTER AUG
More informationCOMPLIANCE BY DESIGN FOR PHARMACEUTICAL QUALITY CONTROL LABORATORIES INSIGHT FROM FDA WARNING LETTERS
COMPLIANCE BY DESIGN FOR PHARMACEUTICAL QUALITY CONTROL LABORATORIES INSIGHT FROM FDA WARNING LETTERS Primer CONTENTS INTRODUCTION...3 QUALITY AND COMPLIANCE IN QUALITY CONTROL LABORATORIES...5 Compliance
More informationPROCESS VALIDATION ROCHAPON WACHAROTAYANKUN, PH.D.
Basic GMP Requirement PROCESS VALIDATION ROCHAPON WACHAROTAYANKUN, PH.D. Topic Process validation What and Why? Principle of process validation Manufacturing process validation Aseptic process validation
More informationGMP & Quality Assurance. Mayur Sushir Dept of Microbiology MJC
GMP & Quality Assurance Mayur Sushir Dept of Microbiology MJC Introduction GMP ensures that quality is built into the organization & processes involved in manufacture GMP covers all aspects of manufacture
More informationTesto Expert Knowledge. The GxP Dictionary 1st edition. Definitions relating to GxP and Quality Assurance
Testo Expert Knowledge The GxP Dictionary 1st edition Definitions relating to GxP and Quality Assurance Note: Some of the information contained in this GxP Dictionary does not apply equally to all countries.
More information9001:2015, ISO 14001:2015 & ISO
Quality management input comprises the standard requirements from ISO 9001:2015 which are deployed by our organization to achieve customer satisfaction through process control. Environmental input comprises
More informationQuality Assurance in Pharmaceutical and Biotech Industries as Per Regulatory Guidelines
Human Journals Review Article January 2017 Vol.:8, Issue:2 All rights are reserved by Chagi Venkatesh et al. Quality Assurance in Pharmaceutical Biotech Industries as Per Regulatory Guidelines Keywords:
More informationGENERIC QUALITY ASSURANCE REQUIREMENTS FOR: BUILT TO PRINT ITEMS, ITEMS TO STANDARD AND OFF THE SHELF ITEMS
GENERIC QUALITY ASSURANCE REQUIREMENTS FOR: BUILT TO PRINT ITEMS, ITEMS TO STANDARD AND OFF THE SHELF ITEMS APPLICABLE FOR: AIRBUS DEFENCE AND SPACE - SPACE BUSINESS UNIT ORBITAL ISSUE: 02c RELEASE DATE:
More informationOverview of Regulatory Requirements for API and Formulations
Overview of Regulatory Requirements for API and Formulations Sangeeta Sardesai 4-Dec-2010 Definition - Regulatory Requirement The restrictions, licenses, and laws applicable to a product or business, imposed
More informationValidation Needs for Sterilization by Aseptic Filtration
Validation Needs for Sterilization by Aseptic Filtration DCVMN Workshop, Hyderabad, 4-8 April 2016 Ramesh Raju Associate Director - Provantage Validation Services Overview Key Regulatory and Industry guidelines
More informationEPICOR, INCORPORATED QUALITY ASSURANCE MANUAL
EPICOR, INCORPORATED QUALITY ASSURANCE MANUAL Revision: 6 Date 05/18/09 EPICOR, INCORPORATED 1414 E. Linden Avenue P.O. Box 1608 Linden, NJ. 07036-0006 Tel. 1-908-925-0800 Fax 1-908-925-7795 Table of Contents:
More informationHealth Products and Food Branch Inspectorate
Our Mandate: To promote good nutrition and informed use of drugs, food, medical devices and natural health products, and to maximize the safety and efficacy of drugs, food, natural health products, medical
More informationAddressing Key FDA Citations with Training. Align UL EduNeering Courses to Top FDA Warning Letter Topics
Addressing Key FDA Citations with Training Align UL EduNeering Courses to Top FDA Warning Letter Topics Addressing Key FDA Citations with Training Align UL EduNeering Courses to Top FDA Warning Letter
More informationTable of Contents. Legal Notices... 61
Notice This manual provides information to excipient manufacturers who intend to participate in the United States Pharmacopeia Ingredient Verification Program for Excipients (USP IVP-E or Program). The
More informationGUIDELINES ON THE PRINCIPLES OF GOOD DISTRIBUTION PRACTICE OF ACTIVE SUBSTANCES FOR MEDICINAL PRODUCTS FOR HUMAN USE
PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME PI 047-1 Annex 1 July 2018 GUIDELINES ON THE PRINCIPLES OF GOOD DISTRIBUTION PRACTICE OF ACTIVE SUBSTANCES FOR MEDICINAL
More informationMANUFACTURE OF INVESTIGATIONAL MEDICINAL PRODUCTS
ANNEX 13 MANUFACTURE OF INVESTIGATIONAL MEDICINAL PRODUCTS Introduction Medicinal products intended for research and development trials are not at present subject either to marketing or manufacturing Community
More informationAAMI Quality Systems White Paper
AAMI s White Paper Comparison of 21 CFR Part 820 to ISO 13485:2016 February 2017, Updated February 2018 AUTHORS Seb Clerkin, GMP Advisory Services Nicola Martin, Owner, Nicola Martin Consulting Jack Ward,
More informationCompounding Pharmacies and the Contract Testing Lab
Compounding Pharmacies and the Contract Testing Lab Scott Sutton, Ph.D. scott.sutton@microbiol.org 1 Disclaimer I am making this presentation as an independent agent I am not making this presentation as
More informationHVAC and Risk Management RACI Meeting 7 th December Agenda. Design. Project Management. Context. Qualification. Construction
HVAC and Risk Management RACI Meeting 7 th December 2011 Dr Stephen Firmer Asia Pacific Consultants Pty Ltd Agenda Context Project Management Design Construction Qualification Routine Control /Potential
More informationWhite paper: Code of GMP Chapter 4 Documentation - PIC/S versus EU
White paper: Code of GMP Chapter 4 Documentation - PIC/S versus EU Numerous articles are available comparing the current and previous EU Code of GMP Chapter 4: Documentation, but no comparison exists between
More informationEstablished Conditions: Reportable CMC Changes for Approved Drug and Biologic Products Guidance for Industry
Established Conditions: Reportable CMC Changes for Approved Drug and Biologic Products Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments
More informationRegulatory Aspects of Cleaning and Cleaning Validation. Larry Greenstein Quality Operations, Quality Unit, Bio-Technology General, Ltd.
Regulatory Aspects of Cleaning and Cleaning Validation Larry Greenstein Quality Operations, Quality Unit, Bio-Technology General, Ltd. 28 June 2017 Why clean? Pharmaceutical production equipment is cleaned
More informationexcipients Setting the Scene
NSF/IPEC/ANSI 363: Good Manufacturing Practices (GMP) for Pharmaceutical Excipients Multiple stakeholders; one objective. Presented by Janeen Skutnik-Wilkinson International Pharmaceutical Excipients Council
More informationRegulatory Perspective on Assuring Ingredient Quality
Regulatory Perspective on Assuring Ingredient Quality PQRI Conference December 15, 2009 Rockville, MD Steven M. Wolfgang, Ph.D., Acting Associate Director, Regulatory Science US Food and Drug Administration
More informationProcess development and basic GMP
Process development and basic GMP Aulton Chapter 45, handouts Specification, stability, inprocess controls and validation Product development Process development Critical Product Qualities issues Critical
More informationHACCP audit checklist
Requirement HACCP audit checklist Prerequisite Program Management Commitment 1. Senior management ensures that the responsibilities and authorities are defined and communicated within the company Internal
More informationROLE OF ICH GUIDELINES IN PHARMACEUTICAL QUALITY RISK MANGAMENT- REVIEW
ejpmr, 2016,3(7), 161-169. SJIF Impact Factor 3.628 Review Article EUROPEAN JOURNAL European OF PHARMACEUTICAL Journal of Pharmaceutical and Medical Research AND MEDICAL RESEARCH ISSN 2394-3211 www.ejpmr.com
More informationPROPOSED NEW SECTIONS FOR WHO GOOD MANUFACTURING PRACTICES (GMP): MAIN PRINCIPLES FOR PHARMACEUTICAL PRODUCTS DRAFT FOR COMMENT
August 2010 RESTRICTED PROPOSED NEW SECTIONS FOR WHO GOOD MANUFACTURING PRACTICES (GMP): MAIN PRINCIPLES FOR PHARMACEUTICAL PRODUCTS DRAFT FOR COMMENT Please address any comments on this draft guideline
More informationQ8 Pharmaceutical Development
Q8 Pharmaceutical Development For questions regarding this draft document contact (CDER) Ajaz Hussain at 301-594-2847 or (CBER) Christopher Joneckis at 301-435-5681. This draft guidance, when finalized,
More informationQualified Persons in the Pharmaceutical Industry. Code of Practice. March 2008
Qualified Persons in the Pharmaceutical Industry Code of Practice March 2008 Updated October 2009 Code of Practice for Qualified Persons 1. INTRODUCTION... 1 2. REGULATORY BASIS FOR THE QUALIFIED PERSON...
More informationRisk Management from the Point of View of a Competent Authority
Risk Management from the Point of View of a Competent Authority Rudolf Völler GMP Inspectorate, Regierungspräsidium, Darmstadt (Germany) Summary A working risk evaluation system is a key element of drug
More informationThe Importance of Supplier Qualification of the Full Distribution Life-cycle in Pharmaceuticals
The Importance of Supplier Qualification of the Full Distribution Life-cycle in Pharmaceuticals William Dale Carter IPEC Americas Chair-Elect & GMP Committee Chair ExcipientFest April 25, 2012 www.ipecamericas.org
More informationPharmaceutical Good Manufacturing Practice. Contents are subject to change. For the latest updates visit
Pharmaceutical Good Manufacturing Practice Page 1 of 6 Why Attend A robust quality system that meets the requirements of pharmaceutical regulators is an essential element of every good pharmaceutical manufacturing
More informationNew GMPs for Active Substances & Excipients. Presented by Eoin Hanley 4 July, 2016
New GMPs for Active Substances & Excipients Presented by Eoin Hanley 4 July, 2016 What we will cover in this session The changing landscape EC Guideline on principles of GDP of active substances Formalised
More informationGMP Track 1 Day 2 Session 1 Vendor Assurance
GMP Track 1 Day 2 Session 1 Vendor Assurance 11 August 2015 150403_POUT This session Three presentations Chapter 6 and 7 - Trevor Schoerie Quality Control Out sourced Activities Draft - FDA Quality Metrics
More informationSupplier Assurance Program. CBE Pty Ltd
Supplier Assurance Program CBE Pty Ltd This training program is copyright to CBE Pty Ltd and may not be modified, reproduced, sold, loaned, hired or traded in any form without its express written permission.
More informationManual 055 Commercial Stability Testing For Formulated Products. This procedure applies to all drug products. The procedure covers:
1 Purpose Manual 055 Commercial Stability Testing For Formulated Products The intent of this procedure is to provide to manufacturing and primary packaging sites the principles of a stability program.
More informationPHARMACEUTICAL DEVELOPMENT
CONTENTS PHARMACEUTICAL DEVELOPMENT Table of Acronyms - Abbreviations Introduction Preface Forward VIII XIII XV XVI XVII Chapter 1 Regulatory 1.1 - Pre-formulation checklist 1.3 Documentation 1.4 - SOP
More informationIndustry Perspective on Manufacturing in Early Development
Industry Perspective on Manufacturing in Early Development IQ Workshop, Feb 4-5, 2014, Washington, D.C. Eric Schmitt AbbVie IQ Drug Product Manufacturing Working Group August 2012 issue of Pharmaceutical
More informationEU Annex 11 US FDA 211, 820, 11; other guidelines Orlando López 11-MAY-2011
Principle. a. This annex applies to all forms of computerised systems used as part of a GMP regulated activities. A computerised system is a set of software and hardware components which together fulfill
More informationQuality Risk Management
Quality Risk Management Audit Expectations and Observations Matthew Davis Lead Auditor Office of Manufacturing Quality, TGA CAPSIG 4 th May 2011 www.tga.gov.au 2 QRM - TGA Expectations and Observations
More informationProcess validation in medical devices
Process validation in medical devices Fulfil requirements with expert regulatory guidance 1TÜV SÜD Contents INTRODUCTION 4 VALIDATION PLANNING 5 INSTALLATION QUALIFICATION 7 OPERATIONAL QUALIFICATION 9
More informationProcess validation in medical devices
Process validation in medical devices Fulfil requirements with expert regulatory guidance 1TÜV SÜD Contents INTRODUCTION 4 VALIDATION PLANNING 5 INSTALLATION QUALIFICATION 7 OPERATIONAL QUALIFICATION 9
More informationEffective Management and Operations of GXP Laboratories
Effective Management and Operations of GXP Laboratories Course Objective: Upon completion of this course, attendees involved in establishing and assuring that Good Laboratory / Good Manufacturing Practice
More informationChanges in the EXCiPACT 2017 Edition Requirements from the 2012 Edition
Changes in the EXCiPACT 2017 Edition Requirements from the 2012 Edition Blue text indicates changes to both GMP and GDP requirements Orange text indicates specific changes to the GDP requirements Items
More informationMedicine Variations Guideline
Medicine Variations Guideline National Health Regulatory Authority (NHRA) Kingdom of Bahrain 30 th March 2017 Version 2.0 Chief of Pharmaceutical Product Regulation: Dr/Roaya Al Abbasi Date: NHRA CEO Approval:
More information